--- title: "Nu-Med Plus (NUMD) stock listing, news and investor profile" url: "https://aibio.space/companies/nu-med-plus/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nu-Med Plus, Inc. (OTC: NUMD), United States. Listing facts, related biotech companies and news on aibio.space." --- NUMD Nu-Med Plus, Inc. OTC · United States # Nu-Med Plus (NUMD) news Nu-Med Plus, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker NUMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Nu-Med Plus news We have not published a story on Nu-Med Plus yet. When there is news, it will appear here. ## Nu-Med Plus at a glance - **Ticker**: NUMD - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $5,409 ### Related companies - [Lifeward](https://aibio.space/companies/lifeward/) NASDAQ: LFWD - [Adastra Holdings](https://aibio.space/companies/adastra/) OTC: XTXXF - [Sensus Healthcare](https://aibio.space/companies/sensus-healthcare/) NASDAQ: SRTS - [ACCURAY INC](https://aibio.space/companies/accuray/) NASDAQ: ARAY - [EBR Systems](https://aibio.space/companies/ebr-systems/) OTC: EBRCZ - [Target Group](https://aibio.space/companies/target/) OTC: CBDY - [Flyte Aviation](https://aibio.space/companies/flyte-aviation/) NYSE: VJET - [SERA PROGNOSTICS, INC.](https://aibio.space/companies/sera-prognostics/) NASDAQ: SERA ### Also on OTC - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) LTUS - [ADAPTIN BIO, INC.](https://aibio.space/companies/adaptin-bio/) APTN - [Alterola Biotech](https://aibio.space/companies/alterola-biotech/) ABTI - [Global Innovative Platforms](https://aibio.space/companies/global-innovative-platforms/) GIPL - [Applied Biosciences](https://aibio.space/companies/applied-biosciences/) APPB - [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) ZVSA ## Nu-Med Plus annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$56,182](https://www.sec.gov/Archives/edgar/data/1543637/000154363726000005/) | [-$68,345](https://www.sec.gov/Archives/edgar/data/1543637/000154363726000005/) | | Cash from operations | [-$47,979](https://www.sec.gov/Archives/edgar/data/1543637/000154363726000005/) | [-$4,433](https://www.sec.gov/Archives/edgar/data/1543637/000154363726000005/) | | Cash and equivalents | [$661](https://www.sec.gov/Archives/edgar/data/1543637/000157587226000575/) | [$2,373](https://www.sec.gov/Archives/edgar/data/1543637/000154812325000021/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5,409. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nu-Med Plus What is the ticker symbol of Nu-Med Plus? Nu-Med Plus, Inc. trades under the ticker NUMD on OTC. Where is Nu-Med Plus listed? Nu-Med Plus, Inc. is listed on OTC. Which country or territory is Nu-Med Plus listed under? Our directory records Nu-Med Plus, Inc. under United States. Does aibio.space cover Nu-Med Plus? aibio.space lists Nu-Med Plus, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Nu-Med Plus profitable? Nu-Med Plus, Inc. reported a net loss of $56,182 for the fiscal year ended Dec 31, 2025, and used $47,979 of cash in operations, per its annual report to the SEC. How much cash does Nu-Med Plus have? $5,409 in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Nu-Med Plus Members talk about Nu-Med Plus (NUMD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nu-Med Plus, newest first. Each line links the filing it comes from. 1. 2026-10-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1543637/000157587226000709/numd_8k.htm) 2. 2026-08-25 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1543637/000157587226000609/numd005_8k.htm) 3. 2026-07-10 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1543637/000157587226000494/numd003_ex99-1.htm) 4. 2026-06-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1543637/000157587226000459/numd002_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:NUMD on TradingView](https://www.tradingview.com/symbols/OTC-NUMD/). ## Listing details Nu-Med Plus, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker NUMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nu-Med Plus, Inc. - **Ticker**: NUMD - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nu-med-plus/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nu-Med Plus (NUMD) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/nu-med-plus/